Radiopharm Theranostics RADX
NASDAQ RADX
$1.44 -0.18 (-11.11%)
As of: Oct 1, 2026 · 10:36 AM EDT

Radiopharm Theranostics (RADX) Research & Development (2023 - 2026)

Updated

Radiopharm Theranostics (RADX) posted Research & Development of $3.05 million for FY2026 (year ended Jun 30, 2026), compared with -$27.52 million in FY2025.

Analysis

Radiopharm Theranostics (RADX) Research & Development (2023 - 2026) Analysis & Trends

Since FY2023, Radiopharm Theranostics has reported Research & Development for 4 fiscal years.

  • Business Quant data shows RADX's Research & Development at -$27.52 million in FY2025, -$23.09 million in FY2024 and -$22.63 million in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 3.65 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 2.34 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 9.74 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -2.85 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -4.05 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 1.87 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 1.76 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 2.81 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 993.80 Mn
10 Radiopharm Theranostics 5.74 Bn 5.70 Bn 186,835.86 -35.44 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -35.44 Mn
Jun 30, 2025 -27.52 Mn
Jun 30, 2024 -23.09 Mn
Jun 30, 2023 -22.63 Mn
API Access

Radiopharm Theranostics Research & Development API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=research-and-development&ticker=RADX&period=max&api_key=YOUR_API_KEY